Key result
Telmisartan inhibits endometrial cancer cell viability and proliferation in preclinical models.
Why the study?
Endometrial cancers increase expression of the renin-angiotensin system, but whether inhibiting it reduces cell viability and proliferation remained to be determined.
Does inhibiting the renin-angiotensin system reduce the viability and proliferation of endometrial cancer cells?
Does inhibiting the renin-angiotensin system reduce the viability and proliferation of endometrial cancer cells?
p-value: p=0.0001
Telmisartan, a dual ARB and PPAR-γ agonist, effectively reduces viability and proliferation of endometrial cancer cells in vitro, whereas standard renin, ACE, and ARB inhibitors have minimal effects.
No takes yet. Share an insight, caveat, or question.
Telmisartan reduces endometrial cancer cell viability in vitro unlike other RAS inhibitors; hypothesis-generating and should not yet change practice.
Delforce et al. (2025) studied Endometrial cancer. Telmisartan vs. Vehicle control was evaluated on Cell proliferation and viability (p=0.0001). Telmisartan significantly reduced the viability of all three endometrial cancer cell lines and reduced the proliferation of Ishikawa cells by 120% at 100 μM.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: